Navigation Links
KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Date:2/27/2008

Third Quarter Revenues Up 38.8%, Nine-Month Revenues Up 40.6% ETHEX Revenue Up 57.8% for Third Quarter, Up 65.2% for Nine Months Ther-Rx

Revenue Up 16.6% for Third Quarter, Up 15.2% for Nine Months

ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) today reported preliminary financial results for the third quarter and first nine months of fiscal 2008 ended December 31, 2007. The results reflected continued acceleration of revenue and profits at both the Company's branded drug subsidiary Ther-Rx Corporation, and generic/non-branded drug subsidiary ETHEX Corporation.

Net revenue, net income and diluted earnings per share amounts for both the third quarter and interim year-to-date periods are preliminary and subject to possible adjustments based upon completion of our financial statements which are being restated to reflect the outcome of a previously disclosed investigation into the Company's stock option grant practices. As previously reported, the New York Stock Exchange has granted an extension for trading of the Company's shares through March 31, 2008 required under the Exchange's rules due to the Company's delayed filing of its fiscal 2007 Annual Report on Form 10-K with the Securities and Exchange Commission. The Company expects by this date to have resolved all outstanding issues needed to make this filing and to complete its fiscal 2007 filings and restatements of previously reported results for the fiscal years 1996-2006.

THIRD QUARTER RESULTS

Net revenues for the third quarter increased 38.8% to $163.7 million, compared to $117.9 million for the third quarter of fiscal 2007. Ther-Rx net revenue grew 16.6% to $56.3 million, while ETHEX net revenues rose 57.8% to $102.2 million. ETHEX net revenue growth was positively affected by important ANDA products including the 100 mg and 200 mg strengths of Metoprolol Succinate Extended Release Tablets (generic alternative to Toprol(R)
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
3. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
4. Lotus Pharmaceuticals Raises $5 Million in Private Placement
5. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
... tends to dissuade sleep, and it may be the best r...ccording to latest research reports. The alertness... color of the light they are working under, accord...elonging to the Brigham & Women's Hospital. Ligh...
...g Menopause? Losing your mind? Just pause and read...nual meeting of the International Neuropsychologic...opause might just get a bit unforgettable. That me...membering things! One more of that middle age blue...
...of Connecticut will be contacting police officers,...e Chief if a pandemic influenza were to break out....lso gearing themselves for such a situation. The f...ront while dealing with emergencies. Humanity has ...
...Bill Keevil and Jonathan Noyce, University School ...have reported that Copper metal has antiviral prop...uenza A virus. In an Invitro study on culture plat... Plaque Forming Units (PFU) of Influenza virus alm...
Other Medicine News:Health News:Menopause pauses memory, posing unforgettable problems 2
(Date:10/6/2008)...ildren, parents discussing clinical ...PRNewswire-USNewswire/ -- From asthma and cancer,t...lives and improves their,health and well-being. A ...h (NIH), "Children and Clinical Studies", (http://...fers parents and health,care providers an insider,...
(Date:10/6/2008)...DE Therapy is More Likely to Induce Steroid-Free...ard Immunomodulator, Azathiopr...resented for the first time,from the Phase 3b Stud...modulators and Biologic Therapy (SONIC) may provid...ts with moderate to severe Crohn,s disease.,Accord...
(Date:10/6/2008)...ed for 9:00 AM ET Today -, SEATTLE, Oct. 6 /PRNew...DNDN) announced today that it has completed the pl... double-blind, placebo-controlled IMPACT,(IMmunoth...known as D9902B),clinical trial designed to assess...tive cellular immunotherapy PROVENGE(R) (sipuleuce...
(Date:10/6/2008)...ompany,s Bioabsorbable Stent - Also,Slated for Pre...wire/ -- Data from multiple clinical trials of,the...ous Bio-engineered R,stent, will be presented next...tics symposium, TCT 2008, in Washington, D.C., Ro...cal Center in,Amsterdam will provide a Genous clin...
Breaking Medicine Technology:Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 1Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 2Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 4Medicares Drug Program Enrollment Up Costs Down 10702 1Medicares Drug Program Enrollment Up Costs Down 10702 2Medicares Drug Program Enrollment Up Costs Down 10702 3Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 10697 1Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 10697 2Britney Spears 3A Lets Talk About All of Us 10692 1Britney Spears 3A Lets Talk About All of Us 10692 2
...esponse, Health Organizations Unite to Help Educat...e Risk of Other Serious,Health Problems, SEATTLE, ...,report looking at the prevalence and cost of type...three out of five people,(57.9 percent) with type ...health problems commonly associated with the disea...
... YORK, April 10, 2007 /PRNewswire-FirstCall/ -- Im...b Company today,announced that a Phase III study o...therapy) in patients with locally advanced,unresec... its,primary endpoint of improving overall surviva...OG), a cancer,center network sponsored by the Nati...
Other Medicine Technology:First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: